Celebrating 25 Years of Scoop
Special: Up To 25% Off Scoop Pro Learn More

News Video | Policy | GPs | Hospitals | Medical | Mental Health | Welfare | Search

 

Kiwi Men Complacent About Skin Cancer

Top Dermatologist Says Kiwi Men Complacent About Skin Cancer

One of New Zealand’s leading dermatologists says Kiwi men are risking their lives by waiting too long to act after becoming concerned about a mole or lesion.

Skin cancer specialist and MoleMap medical director, Dr Mark Gray, says new patient research* shows that one in five men (20%) waited at least six months to act on a lesion of concern, with 5% taking up to a year.

MoleMap is a melanoma surveillance and diagnostic service which combines modern technologies with an expert dermatologist’s diagnosis to screen for melanoma.

Dr Gray says the new survey highlights just how many men delay seeking medical advice for lesions of concern and how this can ultimately result in a worse prognosis if the lesion is in fact a skin cancer.

“Kiwis need to ensure they visit a specialist as soon as they find a mole or lesion of concern as we’ve found that more than one in five of these consultations results in a diagnosis of skin cancer.”

Skin cancer is the most common form of cancer in New Zealand and affects around 60,000 Kiwis a year with around 250 dying from the disease annually.

“Melanoma is often completely without symptoms. Left untreated, in severe cases the cancer can progress to other areas of the body such as the brain, lymph nodes, lungs and liver,” says Dr Gray.

The survey also showed that women were more than twice as likely (50%) than men to act in the first month of becoming concerned about a lesion with one third (33%) taking between one and five months.

Advertisement - scroll to continue reading

Are you getting our free newsletter?

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.

“I can’t stress enough the importance of following your instincts and having a mole of concern checked as soon as you discover it, as well as booking yourself in for a general skin screening every year,” says Dr Gray.

The results of the MoleMap survey are supported by previous research** which revealed that more than half of Kiwis (52%) had never had a mole or lesion checked, yet nearly a quarter (24%) have had a mole removed because of concerns about skin cancer.

The research also showed that New Zealand men are ignoring sun safety messages and are at greatest risk of skin cancer with more than one in four (27%) saying they rarely or never use a sunscreen.

With the largest database of lesions in the world at over 2.5 million, MoleMap data is used for international studies and educational programmes at the world-leading Memorial Sloane-Kettering Cancer Center in the United States and at New York University

Notes to editors

* Survey was conducted internally by MoleMap in November 2010 using a sample size of n=101 New Zealand patients of the clinic.
** Survey was conducted on behalf of the Skin Institute in November 2007 using a sample size of n=500 New Zealanders


Dr Mark Gray: MBChB, FRCPC, FRCPA, Am Bd Cert Path, Am Bd

Dr Mark Gray is a specialist dermatologist. Dr Gray obtained his primary medical degree at the University of Otago in 1982 and in 1990 completed a postgraduate course in Anatomic Pathology and Dermatopathology at Harvard Medical School/Massachusetts, General Hospital and Cornell University/New York. He completed his training in Dermatology and became a Fellow of the Royal College of Physicians in Canada (Dermatology) in 1993.

He is the Medical Director for MoleMap.
ends

© Scoop Media

Advertisement - scroll to continue reading
 
 
 
Culture Headlines | Health Headlines | Education Headlines

 
 
 
 
 
 
 

LATEST HEADLINES

  • CULTURE
  • HEALTH
  • EDUCATION
 
 
  • Wellington
  • Christchurch
  • Auckland
 
 
 

Join Our Free Newsletter

Subscribe to Scoop’s 'The Catch Up' our free weekly newsletter sent to your inbox every Monday with stories from across our network.